Patents by Inventor J. Klein

J. Klein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aryl triazines as LPAAT-beta inhibitors and uses thereof
    Publication number: 20080064700
    Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor cells.
    Type: Application
    Filed: August 6, 2007
    Publication date: March 13, 2008
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott Jenkins, J. Klein, Anil Kumar, John Tulinsky
  • Pyridines and uses thereof
    Publication number: 20070178134
    Abstract: The invention relates to pyridines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor cells.
    Type: Application
    Filed: March 14, 2007
    Publication date: August 2, 2007
    Applicant: Cell Therapeutics, Inc.
    Inventors: Feng Hong, J. Klein
  • LPAAT-beta inhibitors and uses thereof
    Publication number: 20070072856
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.
    Type: Application
    Filed: November 16, 2006
    Publication date: March 29, 2007
    Applicant: Cell Therapeutics, Inc.
    Inventors: Baoqing Gong, John Tulinsky, Lynn Bonham, J. Klein, Robert Finney, David Hollenback, Scott Shaffer, Norina Tang, Thayer White, David Leung
  • Compounds having selective hydrolytic potentials
    Publication number: 20060211713
    Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.
    Type: Application
    Filed: March 8, 2006
    Publication date: September 21, 2006
    Inventors: David Porubek, Anil Kumar, Charles Bredl, J. Klein
  • LPAAT-beta inhibitors and uses thereof
    Publication number: 20060035896
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPMT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.
    Type: Application
    Filed: September 12, 2005
    Publication date: February 16, 2006
    Applicant: Cell Therapeutics, Inc.
    Inventors: Lynn Bonham, J. Klein, Robert Finney, David Hollenback, Scott Shaffer, Norina Tang, Thayer White, David Leung, Baoqing Gong, John Tulinsky
  • Pyridines and uses thereof
    Publication number: 20050182102
    Abstract: The invention relates to pyridines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor cells.
    Type: Application
    Filed: February 11, 2005
    Publication date: August 18, 2005
    Applicant: Cell Therapeutics, Inc.
    Inventors: Feng Hong, J. Klein
  • Pyridopyrimidine compounds and their uses
    Publication number: 20050059685
    Abstract: Novel pyridopyrimidine-based compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.
    Type: Application
    Filed: August 19, 2004
    Publication date: March 17, 2005
    Applicant: Cell Therapeutics, Inc.
    Inventors: Marc McKennon, J. Klein, Michael Coon
  • Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
    Publication number: 20050049262
    Abstract: Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by lnterleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S.
    Type: Application
    Filed: August 16, 2004
    Publication date: March 3, 2005
    Applicant: Cell Therapeutics, Inc.
    Inventors: J. Klein, Stephen Klaus, Anil Kumar, Baoqing Gong
  • Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
    Publication number: 20050032748
    Abstract: Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N,N(R3) and S.
    Type: Application
    Filed: August 3, 2004
    Publication date: February 10, 2005
    Applicant: Cell Therapeutics, Inc.
    Inventors: J. Klein, Stephen Klaus, Anil Kumar, Baoqing Gong